Since it was first reported in 2009 after isolation from ear cultures of 1 Japanese patient and 15 Korean patients, Candida auris infections have been reported in at least 35 countries on 6 continents. The global emergence of C. auris raises several serious concerns for public health due to the high rates of antifungal drug resistance, organism misidentification, and high transmissibility among hospitalised patients, leading to nosocomial outbreaks and significant patient mortality. Furthermore, during the last 10 years, outbreaks or invasive healthcare-associated infections due to C. auris have been frequently reported in many countries, highlighting that adequate laboratory capacity and infection control preparedness are required to prevent spread within hospitals.